Chest ACCP Education Calendar
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text Free
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (11)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mohamed, K. H.
Right arrow Articles by Light, R. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mohamed, K. H.
Right arrow Articles by Light, R. W.
(Chest. 2001;119:776-780.)
© 2001 American College of Chest Physicians

BAL Neopterin*

A Novel Marker for Cell-Mediated Immunity in Patients With Pulmonary Tuberculosis and Lung Cancer

K. Hassaan Mohamed, MBBCh, MSc; A. A. M. T. Mobasher, MD, FCCP; Abdel-Rahim I. Yousef, MD; Adel Salah, MD; I. Z. El-Naggar, MD; A. H. A. Ghoneim, MD and Richard W. Light, MD, FCCP

* From the Departments of Chest (Drs. Mohamed, Mobasher, Yousef, Salah, and Ghoneim) and Biochemistry (Dr. El-Naggar), Zagazig University Hospital, Zagazig, Egypt; and the Pulmonary Medicine Department (Dr. Light), Saint Thomas Hospital and Vanderbilt University, Nashville, TN.

Correspondence to: Richard W. Light, MD, FCCP, Pulmonary Disease Program, Saint Thomas Hospital, PO Box 380, 4220 Harding Rd, Nashville, TN 37205; e-mail: rlight98{at}yahoo.com

Background: Neopterin is derived from guanosine triphosphate and is produced by stimulated macrophages under the influence of {gamma}-interferon of lymphocyte origin. It has been suggested that it is an excellent marker for the activation of the monocyte/macrophage axis in some clinical situations. However, to our knowledge, the relationship of BAL neopterin levels to disease states has not been studied.

Aim: To assess the usefulness of BAL neopterin levels as an index of disease activity in patients with pulmonary tuberculosis and lung cancer.

Methods: BAL and serum neopterin levels were evaluated in 20 patients with pulmonary tuberculosis, 20 patients with bronchogenic carcinoma, and 10 healthy individuals. The concentration of neopterin was evaluated by radioimmunoassay technique. The BAL level of neopterin was standardized using the BAL urea level.

Results: The neopterin levels (mean ± SD) in the BAL and serum of tuberculous patients (88.6 ± 27.4 nmol/L epithelial lining fluid [ELF], 61.3 ± 29.4 nmol/L, respectively) were significantly higher when compared with those in lung cancer patients (40.7 ± 16.6 nmol/L ELF, 26.8 ± 6.58 nmol/L, respectively, p < 0.001) and when compared with those in control subjects (26.3 ± 11.3 nmol/L ELF, 6.8 ± 2.7 nmol/L, respectively, p < 0.001). In the tuberculous group, BAL and serum neopterin levels in patients with far-advanced disease were significantly higher when compared with those in patients with moderately and minimally advanced diseases (p < 0.001). BAL and serum neopterin levels were significantly higher in patients with small cell carcinoma than in those with adenocarcinoma (p < 0.05). BAL neopterin levels were significantly (p < 0.001) higher than serum levels in all patients and control groups. In addition, there were significant positive correlations between BAL and serum neopterin levels in tuberculous (r = 0.92, p < 0.001), lung cancer (r = 0.62, p < 0.001), and control groups (r = 0.93, p < 0.001).

Conclusions: The levels of neopterin in BAL fluid may reflect the degree of disease activity in pulmonary tuberculous patients. In addition, BAL neopterin levels are elevated in patients with lung cancer, especially the small-cell carcinoma type.

Key Words: BAL • lung cancer • pulmonary tuberculosis • neopterin




This article has been cited by other articles:


Home page
 J. Biol. Chem.Home page
M. Kirsch, H.-G. Korth, V. Stenert, R. Sustmann, and H. de Groot
The Autoxidation of Tetrahydrobiopterin Revisited: PROOF OF SUPEROXIDE FORMATION FROM REACTION OF TETRAHYDROBIOPTERIN WITH MOLECULAR OXYGEN
J. Biol. Chem., June 27, 2003; 278(27): 24481 - 24490.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2001 by the American College of Chest Physicians.